Is houndstongue safe to take as a herbal supplement?

No, houndstongue (Cynoglossum officinale) is not safe for internal use due to its high concentration of pyrrolizidine alkaloids (PAs) such as consolidine and heliosupine. These compounds cause irreversible hepatic veno-occlusive disease and are genotoxic carcinogens; the European Medicines Agency explicitly advises against oral consumption of PA-containing plants with no established safe dose for humans.

What are the toxic compounds in houndstongue?

The primary toxic compounds in Cynoglossum officinale are pyrrolizidine alkaloids, specifically consolidine, heliosupine, echinatine, and their N-oxide forms. These alkaloids are bioactivated by hepatic cytochrome P450 enzymes (CYP3A4, CYP2B6) into reactive dehydropyrrolizidine pyrroles that bind covalently to cellular DNA and proteins, causing hepatocyte death and progressive liver scarring.

What did European herbalists traditionally use houndstongue for?

In European folk and medieval herbal medicine, houndstongue was applied traditionally for fever reduction, chest congestion, coughs, and as a topical remedy for skin wounds and hemorrhoids. These uses are entirely anecdotal, documented in historical texts such as Gerard's Herball (1597), with no controlled clinical trials ever validating efficacy or establishing a therapeutic dose that avoids hepatotoxicity.

Can houndstongue cause liver damage?

Yes, houndstongue is a well-documented hepatotoxin in both animals and humans. Its pyrrolizidine alkaloids are metabolized into pyrrole intermediates that cause sinusoidal obstruction syndrome (hepatic veno-occlusive disease), characterized by blockage of small hepatic veins, liver enlargement, jaundice, and potentially fatal liver failure. Livestock deaths from Cynoglossum officinale ingestion are well-reported in veterinary literature.

Are there any legitimate health benefits of houndstongue supported by research?

There are no validated health benefits of Cynoglossum officinale supported by human clinical research. While in vitro studies have observed some antimicrobial and anti-inflammatory activity from plant extracts, these findings have not been translated into safe human applications, and the plant's toxicity profile—specifically its pyrrolizidine alkaloid content—far outweighs any potential therapeutic benefit identified in preliminary laboratory models.

Is houndstongue safe to take during pregnancy or while breastfeeding?

Houndstongue is not recommended during pregnancy or breastfeeding due to its pyrrolizidine alkaloid content, which can cross the placenta and be excreted in breast milk, potentially harming fetal development or nursing infants. No safety studies have been conducted in pregnant or lactating women, and the known hepatotoxic properties make it unsuitable for these vulnerable populations. Medical professionals universally advise against use during these periods.

Does houndstongue interact with medications metabolized by the liver?

Houndstongue may interact with medications processed through hepatic pathways, as its pyrrolizidine alkaloids can impair liver function and potentially interfere with drug metabolism. This is particularly concerning for individuals taking medications that depend on cytochrome P450 enzymes for breakdown, such as certain anticoagulants, anticonvulsants, and immunosuppressants. Anyone taking prescription medications should avoid houndstongue and consult their healthcare provider before considering any botanical supplement.

What is the quality of clinical evidence supporting houndstongue's traditional uses?

Clinical evidence for houndstongue is extremely limited, with no human randomized controlled trials validating its traditional use for fever, cough, or respiratory conditions. The available research focuses primarily on documenting its toxic alkaloid profile rather than demonstrating therapeutic efficacy. Any health claims about houndstongue rely entirely on historical anecdotal use rather than modern scientific validation, making it unsuitable as a reliable treatment option.

Houndstongue (Cynoglossum officinale)

Houndstongue (Cynoglossum officinale) contains pyrrolizidine alkaloids (PAs), primarily consolidine and heliosupine, which cause hepatotoxicity through metabolic activation to toxic pyrrole intermediates that alkylate DNA and proteins. The plant has a long history in European folk medicine for respiratory and fever complaints, but its toxicity profile renders it unsafe for therapeutic use in humans.

Category: European Evidence: 2/10 Tier: Traditional

Houndstongue (Cynoglossum officinale) — Hermetica Encyclopedia

Origin & History

Houndstongue (Cynoglossum officinale) is a biennial herbaceous plant native to Eurasia, notably western Asia and eastern Europe. It is an invasive weed in North America, often found in riparian zones, grasslands, and agricultural areas.

Historical & Cultural Context

Root extracts of Houndstongue have been used traditionally to treat fever and respiratory ailments, though specifics are unclear. Leaves were used as a mole repellent and to protect stored produce from rodents.

Health Benefits

• Due to the lack of human clinical trials, no specific health benefits are validated. • Traditional uses for fever and chest/respiratory ailments are anecdotal and not supported by clinical evidence. • The plant is primarily noted for its toxic effects rather than therapeutic benefits. • No safe therapeutic use in humans has been documented. • Pyrrolizidine alkaloids are associated with liver toxicity rather than health benefits.

How It Works

Houndstongue's primary bioactive compounds are pyrrolizidine alkaloids (PAs) such as consolidine, heliosupine, and echinatine, which are metabolized in the liver by cytochrome P450 enzymes (CYP3A4, CYP2B6) into reactive dehydropyrrolizidine pyrrole esters. These electrophilic pyrrole metabolites cross-link DNA strands and alkylate hepatic proteins, leading to hepatocyte necrosis and veno-occlusive disease (sinusoidal obstruction syndrome). Cumulative PA exposure causes progressive occlusion of hepatic venules, impairing liver blood flow and triggering hepatic failure.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for Cynoglossum officinale. Available studies focus on the biosynthesis of its toxic alkaloids rather than clinical outcomes.

Clinical Summary

No controlled human clinical trials have evaluated Cynoglossum officinale for any therapeutic indication, leaving its traditional uses entirely unsupported by clinical evidence. Toxicity data derive primarily from livestock case reports and in vitro genotoxicity studies, which consistently demonstrate DNA alkylation and chromosomal aberrations at low PA concentrations. The European Food Safety Authority (EFSA) and the European Medicines Agency (EMA) have issued warnings against internal use of PA-containing plants, including Cynoglossum species, due to an unfavorable risk-to-benefit ratio with no established safe dose. Animal studies in rats and cattle confirm cumulative hepatotoxicity, hepatic veno-occlusive disease, and death following repeated exposure to PA-containing plant material.

Nutritional Profile

Houndstongue (Cynoglossum officinale) is not consumed as a food source due to its toxicity, so conventional macronutrient profiling is not applicable in a dietary context. However, phytochemical composition is documented: Pyrrolizidine alkaloids (PAs) are the primary bioactive compounds, present throughout the plant at concentrations of approximately 0.1–0.5% dry weight, with heliosupine, echinatine, rinderine, and cynoglossine identified as the major PAs. Cynoglossine (a quaternary alkaloid) has been isolated and characterized as a curare-like neurotoxic compound. Consolidine and consolicine are also present in smaller quantities. The plant contains tannins (condensed and hydrolyzable forms, estimated 2–5% dry weight), which contribute to its astringent properties noted in historical topical use. Allantoin has been reported in trace amounts, consistent with other Boraginaceae family members. Mucilaginous polysaccharides are present in the leaves and roots, contributing to the plant's historically noted demulcent texture. Rosmarinic acid and other hydroxycinnamic acid derivatives have been detected in minor concentrations (<0.1% dry weight). Wax esters and fatty acids are present in surface coatings of the burr-like nutlets. Mineral content has not been specifically characterized in literature. Bioavailability of PAs is notably high via oral ingestion, with N-oxide forms converting to toxic free-base forms in the gastrointestinal tract and liver, making even small ingested quantities hepatotoxic.

Preparation & Dosage

No clinically studied dosage ranges exist due to the absence of human trials and its classification as toxic. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

None due to toxicity

Safety & Interactions

Cynoglossum officinale is considered unsafe for internal human use due to its pyrrolizidine alkaloid content; no safe therapeutic dose has been established and the EMA advises against any oral ingestion. PAs are potent hepatotoxins and classified as genotoxic carcinogens; exposure risks include acute liver failure, hepatic veno-occlusive disease, and long-term carcinogenesis. The plant is absolutely contraindicated in pregnancy and lactation, as PA metabolites cross the placenta and are excreted in breast milk, posing severe risk of fetal hepatotoxicity and developmental harm. Concomitant use with hepatotoxic drugs (e.g., acetaminophen, statins, azole antifungals that inhibit CYP3A4) would theoretically amplify liver damage by altering PA metabolic activation.